Corcept Therapeutics
About Company
Corcept Therapeutics is a biopharmaceutical company focused on the research and development of cortisol modulators. They have discovered over 1,000 proprietary cortisol modulators and received FDA approval for Korlym® (mifepristone) in 2012, the first approved treatment for Cushing’s syndrome. The company is currently conducting over 30 studies across various disease areas including endocrinology, oncology, metabolism, and neurology. Corcept is a fast-growing biotech company located in the Bay Area. They are committed to high ethical and technical standards throughout their operations, encompassing development, manufacturing, clinical research, and commercial activities.
